Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

BACKGROUND: The inhibitor telaprevir (VX-950) of the hepatitis C virus (HCV) protease NS3-4A has been tested in a recent phase 1b clinical trial in patients infected with HCV genotype 1. This trial revealed residue mutations that confer varying degrees of drug resistance. In particular, two protease...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Welsch, Christoph, Domingues, Francisco S, Susser, Simone, Antes, Iris, Hartmann, Christoph, Mayr, Gabriele, Schlicker, Andreas, Sarrazin, Christoph, Albrecht, Mario, Zeuzem, Stefan, Lengauer, Thomas
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2008
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2395260/
https://ncbi.nlm.nih.gov/pubmed/18215275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/gb-2008-9-1-r16
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items